H. Lundbeck A/S initiates a phase I study of a potential new treatment of Parkinson’s disease

Lu AF28996 is the third compound added to Lundbeck’s clinical development pipeline in 2018.

VALBY, 28-Jun-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a potential new treatment of Parkinson’s disease. The compound — Lu AF28996— is invented by Lundbeck and will now be studied in healthy volunteers as first part of its clinical development.

Lu AF28996 has the potential to treat common symptoms in patients with moderate/advanced Parkinson’s disease. Typically, patients gradually develop fluctuations in the control of their symptoms with poor or absent motor function (so called OFF episodes) and experience involuntary movements (dyskinesia). Both these symptoms are thought to be treated effectively with Lu AF28996.

“It is a pleasure to bring another promising Lundbeck invention into clinical testing. This compound has the potential to significantly improve the lives of patients with Parkinson’s disease, many of whom today do not have effective treatment options. Hopefully we will be able to offer these patients much better symptom control in the future”, says Anders Gersel Pedersen, Executive Vice President, Research and Development at Lundbeck.

Following the start of a phase I-study with the potential new schizophrenia and Alzheimer’s disease treatment Lu AF76432 last month, Lu AF28996 is the second internal compound that Lundbeck adds to its clinical development pipeline in 2018. Further to this, Lundbeck acquired foliglurax, another potential new treatment of Parkinson’s disease, in March 2018. Lundbeck may move yet another of its in-house compounds into clinical development before the end of the year.

Contacts

Mads Kronborg
Senior Director, Corporate Communication
Phone: +45 36 43 40 00
E-mail: mavk@lundbeck.com

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders — we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. Our research centre is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

SOURCE: H. Lundbeck A/S